Literature DB >> 31036691

In Vivo Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model.

Alexander J Lepak1, Miao Zhao1,2, Karen Marchillo2, Jamie VanHecker2, David R Andes3,4,2.   

Abstract

Omadacycline is a novel aminomethylcycline antibiotic with potent activity against Staphylococcus aureus, including methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA). We investigated the pharmacodynamic activity of omadacycline against 10 MSSA/MRSA strains in a neutropenic murine thigh model. The median 24-h area under the concentration-time curve (AUC)/MIC values associated with net stasis and 1-log kill were 21.9 and 57.7, respectively.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Staphylococcus aureuszzm321990; omadacycline; pharmacodynamics

Year:  2019        PMID： 31036691      PMCID： PMC6591633          DOI： 10.1128/AAC.00624-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model.

Authors:  Alexander J Lepak; Miao Zhao; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  Alexander J Lepak; Miao Zhao; Qingmei Liu; Ping Wang; Yanli Wang; Justin C Bader; Paul G Ambrose; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2019-02-26       Impact factor: 5.191

3.  Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.

Authors:  Michael D Huband; Michael A Pfaller; Dee Shortridge; Robert K Flamm
Journal:  J Glob Antimicrob Resist       Date:  2019-02-27       Impact factor: 4.035

4.  Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011.

Authors:  Michael A Pfaller; Michael D Huband; Paul R Rhomberg; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

5.  Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.

Authors:  A K Meagher; J A Passarell; B B Cirincione; S A Van Wart; K Liolios; T Babinchak; E J Ellis-Grosse; P G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

6.  In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model.

Authors:  Miao Zhao; Alexander J Lepak; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

7.  Omadacycline for Community-Acquired Bacterial Pneumonia.

Authors:  Roman Stets; Monica Popescu; Joven R Gonong; Ismail Mitha; William Nseir; Andrzej Madej; Courtney Kirsch; Anita F Das; Lynne Garrity-Ryan; Judith N Steenbergen; Amy Manley; Paul B Eckburg; Evan Tzanis; Paul C McGovern; Evan Loh
Journal:  N Engl J Med       Date:  2019-02-07       Impact factor: 91.245

8.  Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.

Authors:  William O'Riordan; Sinikka Green; J Scott Overcash; Ivan Puljiz; Symeon Metallidis; J Gardovskis; Lynne Garrity-Ryan; Anita F Das; Evan Tzanis; Paul B Eckburg; Amy Manley; Stephen A Villano; Judith N Steenbergen; Evan Loh
Journal:  N Engl J Med       Date:  2019-02-07       Impact factor: 91.245

9.  Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline.

Authors:  Laura Honeyman; Mohamed Ismail; Mark L Nelson; Beena Bhatia; Todd E Bowser; Jackson Chen; Rachid Mechiche; Kwasi Ohemeng; Atul K Verma; E Pat Cannon; Ann Macone; S Ken Tanaka; Stuart Levy
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

10.  Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program.

Authors:  Michael A Pfaller; Michael D Huband; Dee Shortridge; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191
View more
  11 in total

1.  Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018.

Authors:  Michael A Pfaller; Michael D Huband; Dee Shortridge; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 2.  Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance.

Authors:  Kerry L LaPlante; Abhay Dhand; Kelly Wright; Melanie Lauterio
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

3.  In Vivo Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model.

Authors:  Alexander J Lepak; Miao Zhao; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

4.  Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection.

Authors:  Emily C Maggioncalda; Elizabeth Story-Roller; Danielle A Nicklas; Benjamin Eichelman; Chavis Tabor; Alisa W Serio; Tiffany R Keepers; Surya Chitra; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2021-10-18       Impact factor: 5.191

5.  Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using in vivo microdialysis.

Authors:  Christian M Gill; Andrew J Fratoni; Ashley K Shepard; Joseph L Kuti; David P Nicolau
Journal:  J Antimicrob Chemother       Date:  2022-04-27       Impact factor: 5.790

6.  Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens.

Authors:  Taylor Morrisette; Sara Alosaimy; Abdalhamid M Lagnf; Jeremy J Frens; Andrew J Webb; Michael P Veve; Ryan Stevens; Jeannette Bouchard; Tristan W Gore; Iman Ansari; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2022-05-14

7.  Efficacy of Omadacycline against Multidrug-Resistant Enterococcus faecium Strains in a Mouse Peritonitis Model.

Authors:  Kavindra V Singh; Cesar A Arias; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

8.  Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model.

Authors:  Brian D VanScoy; Elizabeth A Lakota; Haley Conde; Jennifer McCauley; Lawrence Friedrich; Judith N Steenbergen; Paul G Ambrose; Sujata M Bhavnani
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

Review 9.  Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections.

Authors:  Corneliu Ovidiu Vrancianu; Elena Georgiana Dobre; Irina Gheorghe; Ilda Barbu; Roxana Elena Cristian; Mariana Carmen Chifiriuc
Journal:  Microorganisms       Date:  2021-03-31

10.  Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis.

Authors:  Melissa J Karau; Suzannah M Schmidt-Malan; Scott A Cunningham; Jayawant N Mandrekar; Bobbi S Pritt; Tiffany R Keepers; Alisa W Serio; Surya Chitra; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2021-11-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.